Multiple myeloma: From diagnosis to treatment

Australian Family Physician

Volumn 42, Issue 10, 2013, Pages 684-688

  Eslick, Renee ^a   Talaulikar, Dipti ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Diagnosis; Differential; Monoclonal gammopathy of undetermined significance; Multiple myeloma

Indexed keywords

PARAPROTEIN;

ANEMIA; BLOOD; BLOOD CELL COUNT; BONE; BONE MARROW; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; METABOLISM; MULTIPLE MYELOMA; PATHOLOGIC FRACTURE; PATHOLOGY; RADIOGRAPHY; REVIEW;

ANEMIA; BLOOD CELL COUNT; BONE AND BONES; BONE MARROW; FRACTURES, SPONTANEOUS; HUMANS; HYPERCALCEMIA; MULTIPLE MYELOMA; PARAPROTEINS; RENAL INSUFFICIENCY;

EID: 84886884898     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clinic Proc 2005;80:1371-82.
2. Kyle RA, Morie GA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 2003;78:21-33.
3. Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med 2004;27:153-60.
4. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations and prognostic significance. Leuk Lymph 2007;48:337-41.
5. Palumbo A, Anderson K. Medical progress: Multiple myeloma. N Engl J Med 2011;364:1046-60.
6. Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haem 2012;159:499-513.
7. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011;117:5573-81.
8. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
9. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:226-35
10. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
11. Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. J Clin Onc 2005;23:1-9.
12. Quach H, Prince M coordinated on behalf of the MSAG. Clinical practice guideline: multiple myeloma. Available at: www.myeloma.org.au/ LinkClick.aspx?fileticket=55A0pOby0WQ%3d&tabid=84 [Accessed 12 September 2013].
13. Stewart AK, Trudel S, Bahlis NH, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinical Trials Group Myeloma 10 Trial. Blood 2013;121:1517-23.
14. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Eng J Med 2012;366:1782-91.
15. McCarthy PL, Owzar K, Hofmeister CC. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-81.
16. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane DatabaseSyst Rev 2012;5:CD003188